Clinical Trials Browser

Phase 2 × Recurrence × Lymphoid × Clear all

NCT03458260 2026-03-10

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase 2 Completed

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT07453095 2026-03-05

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

Phase 2 Not yet recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05714345 2026-03-02

EXPAND

Phase 2 Terminated

2 enrolled 8 charts

Lymphoma, Recurrence

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Recurrence

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04842877 2026-02-19

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT05144841 2026-02-13

MK-2140-004

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07341191 2026-02-12

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Phase 2 Not yet recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Phase 2 Active not recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05460533 2026-02-04

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Active not recruiting

Burkitt Lymphoma, Recurrence

NCT06854653 2026-02-03

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2 Recruiting

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Phase 2 Completed

48 enrolled 12 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Phase 2 Recruiting

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Recurrence

NCT07254754 2025-11-28

LATE-R-GEL-23

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03734198 2025-11-26

IDA53

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07082686 2025-11-21

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Phase 2 Recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03568461 2025-10-07

ELARA

Phase 2 Completed

98 enrolled 9 charts 1 FDA

Lymphoma, Follicular, Recurrence

NCT06534437 2025-09-29

JASPIS-01

Phase 2 Recruiting

Aggression, Lymphoma, Non-Hodgkin, Recurrence

NCT05498220 2025-09-02

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Phase 2 Completed

60 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05020015 2025-08-12

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2 Active not recruiting

27 enrolled 23 charts

Recurrence, Lymphoma, B-Cell

NCT04684147 2025-08-08

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Phase 2 Active not recruiting

Lymphoma, Recurrence

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Phase 2 Active not recruiting

260 enrolled 13 charts

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellSarcoma

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Precancerous Conditions, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT04689659 2025-05-18

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

Phase 2 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, T-Cell

NCT05972720 2025-05-15

FIRCE-1

Phase 2 Terminated

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05149378 2025-05-14

Venetoclax Based Regimen for R/R T-ALL

Phase 2 Completed

LymphoidOther hematologic neoplasm

Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06931613 2025-04-17

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Phase 2 Enrolling by invitation

Hodgkin Disease, Recurrence

NCT06918912 2025-04-09

LORELY

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03744676 2025-02-27

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Phase 2 Completed

104 enrolled 29 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03443128 2025-02-13

Vinorelbine for Recurrent ALCL-2017

Phase 2 Completed

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT05451810 2025-01-24

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Phase 2 Active not recruiting

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03484702 2024-12-27

TRANSCENDWORLD

Phase 2 Completed

113 enrolled 35 charts

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05008055 2024-12-20

CAPITAL

Phase 2 Completed

30 enrolled 15 charts

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell